Payment overview · 2025
General Payments
$382.73
18 reported records · 8 companies
Healthcare provider profile · identity verified
Carson Douglas Seeber, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CLARKSTON, WA · NPI 1861740300
Verified facts
What the public records show
CMS Open Payments records show Carson Douglas Seeber, M.D. received $382.73 in general payments during 2025 across 18 reported records.
AstraZeneca Pharmaceuticals LP accounted for 37.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $143.16 | 37.4% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $79.32 | 20.7% | 5 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $50.05 | 13.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $32.90 | 8.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.14 | 6.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.14 | 5.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.18 | 4.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.84 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $382.73 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $115.95 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $87.97 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $79.32 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $79.32 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $60.76 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $50.05 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $32.90 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.14 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $16.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
130 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 414 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 387 | 106 |
| Omeprazole | Omeprazole | 350 | 93 |
| Atorvastatin Calcium | Atorvastatin Calcium | 323 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 289 | 88 |
| Hydrochlorothiazide | Hydrochlorothiazide | 169 | 49 |
| Metformin Hcl | Metformin Hcl | 166 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 162 | 49 |
| Simvastatin | Simvastatin | 162 | 45 |
| Lisinopril | Lisinopril | 158 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 151 | 45 |
| Metformin Hcl Er | Metformin Hcl | 146 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 137 | 42 |
| Eliquis | Apixaban | 130 | 26 |
| Spironolactone | Spironolactone | 130 | 34 |
| Potassium Chloride | Potassium Chloride | 123 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 119 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 111 | 35 |
| Ozempic | Semaglutide | 110 | 21 |
| Gabapentin | Gabapentin | 105 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 28 |
| Tramadol Hcl | Tramadol Hcl | 90 | 28 |
| Carvedilol | Carvedilol | 79 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 79 | 22 |
| Furosemide | Furosemide | 78 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 27 |
| Sertraline Hcl | Sertraline Hcl | 72 | 20 |
| Allopurinol | Allopurinol | 70 | 22 |
| Trazodone Hcl | Trazodone Hcl | 70 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 64 | 13 |
| Lorazepam | Lorazepam | 63 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | suppressed |
| Celecoxib | Celecoxib | 57 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 56 | 11 |
| Glipizide Er | Glipizide | 49 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | 17 |
| Prednisone | Prednisone | 46 | 24 |
| Alprazolam | Alprazolam | 45 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 11 |
| Warfarin Sodium | Warfarin Sodium | 45 | 11 |
| Alendronate Sodium | Alendronate Sodium | 44 | 15 |
| Telmisartan | Telmisartan | 40 | 12 |
| Montelukast Sodium | Montelukast Sodium | 39 | 13 |
| Donepezil Hcl | Donepezil Hcl | 38 | suppressed |
| Mirtazapine | Mirtazapine | 37 | 11 |
| Ezetimibe | Ezetimibe | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | 11 |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 13 |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 28 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Ketoconazole | Ketoconazole | 28 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 27 | suppressed |
| Estradiol | Estradiol | 27 | 11 |
| Methocarbamol | Methocarbamol | 27 | 12 |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Meloxicam | Meloxicam | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 20 |
| Acyclovir | Acyclovir | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 15 |
| Digoxin | Digoxin | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Famotidine | Famotidine | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 12 |
| Glimepiride | Glimepiride | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Baclofen | Baclofen | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Pulmicort Flexhaler | Budesonide | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $382.73 · 18 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPVAXIVE, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, INGREZZA, MINIMED 780G, NURTEC ODT, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error